(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.29%) $78.71
(-1.28%) $2.17
(0.09%) $2 333.30
(0.06%) $27.63
(0.79%) $972.50
(0.02%) $0.928
(0.13%) $10.84
(0.06%) $0.796
(0.00%) $91.35
Quarter results tomorrow
(amc 2024-05-08)
Expected move: +/- 7.20%
0.24% $ 16.87
@ $16.78
Wydano: 14 vas. 2024 @ 18:57
Zwrot: 0.54%
Poprzedni sygnał: vas. 13 - 22:50
Poprzedni sygnał:
Zwrot: 3.13 %
Live Chart Being Loaded With Signals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease...
Stats | |
---|---|
Dzisiejszy wolumen | 200 213 |
Średni wolumen | 742 880 |
Kapitalizacja rynkowa | 826.51M |
EPS | $0 ( 2024-05-01 ) |
Następna data zysków | ( $-1.280 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.80 |
ATR14 | $0.0250 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Mills Kenneth T. | Buy | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Common Stock |
2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Stock Options (Right to Buy) |
2024-03-19 | Vasista Vittal | Buy | 20 041 | Common Stock |
2024-03-19 | Vasista Vittal | Sell | 20 041 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
56.02 |
Last 99 transactions |
Buy: 2 306 609 | Sell: 467 606 |
Wolumen Korelacja
Regenxbio Inc Korelacja
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Regenxbio Inc Korelacja - Waluta/Towar
Regenxbio Inc Finanse
Annual | 2023 |
Przychody: | $90.24M |
Zysk brutto: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2023 |
Przychody: | $90.24M |
Zysk brutto: | $35.71M (39.57 %) |
EPS: | $-6.02 |
FY | 2022 |
Przychody: | $112.72M |
Zysk brutto: | $58.18M (51.61 %) |
EPS: | $-6.50 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $3.01 |
Financial Reports:
No articles found.
Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej